secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2026-04-08T23:59:59+00:00
Accession:  0001549595-26-000024
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix Q1 net loss $87.2M ($0.79); advancing bexobrutideg registrational program
-------------------------------------------------------------------------------

- Revenue $6.3M vs $18.5M YoY; net loss $87.2M ($0.79) vs $56.4M ($0.67).
- Cash $540.7M vs $592.9M at Nov 30, 2025; net burn ~$52M in quarter.
- Enrolling Phase 2 DAYBreak CLL-201 for bexobrutideg; Phase 3 confirmatory trial planned mid-2026.
- Healthy volunteer SAD/MAD study of new tablet formulation to support IND in immunology/inflammation.
- Sanofi advancing STAT6 degrader NX-3911; Gilead advancing IRAK4 degrader GS-6791 in Phase 1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959526000024/0001549595-26-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959526000024/nrix-20260408.htm
  HTML page:      https://secwatch.observer/filing/0001549595-26-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer